目的 探討低分子肝素鈣聯(lián)合山莨菪堿治療早發(fā)型重度子癇前期的臨床療效。方法 選取2011年6月-2017年6月在西北婦女兒童醫(yī)院治療的早發(fā)型重度子癇前期患者156例為研究對象，隨機(jī)分為對照組（78例）和治療組（78例））。對照組患者肌內(nèi)注射鹽酸消旋山莨菪堿注射液，10 mg/次，2次/d。治療組在對照組的基礎(chǔ)上腹壁皮下注射低分子肝素鈣注射液，2 050 AXaIU/次，2次/d。兩組患者連續(xù)治療1周。比較兩組的血壓、腎功能指標(biāo)、妊娠結(jié)局及妊娠并發(fā)癥情況。結(jié)果 治療后，對照組收縮壓和平均動脈壓明顯下降，治療組收縮壓、舒張壓和平均動脈壓均明顯下降，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05）；治療后，治療組患者舒張壓和平均動脈壓水平明顯低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者24 h尿蛋白、尿酸（UA）、尿素氮（BUN）、血肌酐（Scr）水平均顯著降低，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組患者比對照組降低更明顯，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，治療組患者的新生兒體質(zhì)量、存活數(shù)、分娩孕周和延長孕齡天數(shù)均明顯優(yōu)于對照組患者，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。對照組和治療組并發(fā)癥的發(fā)生率分別為15.18%、7.59%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 低分子肝素鈣聯(lián)合山莨菪堿治療早發(fā)型重度子癇前期具有較好的臨床療效，具有一定的臨床推廣應(yīng)用價值。

Objective To explore the clinical efficacy of low molecular weight heparin calcium combined with anisodamine in treatment of early onset severe preeclampsia. Methods Patients (156 cases) with early onset severe preeclampsia in Northwest Women and Children Hospital from June 2011 to June 2017 were randomly divided into control (78 cases) and treatment (78 cases) groups. Patients in the control group were intramuscular injection administered with Raceanisodamine Hydrochloride Injection, 10 mg/time, twice daily. Patients in the treatment group were abdominal subcutaneous injection administered with Low-Molecular-Weight Heparins Calcium Injection on the basis of the control group, 2 050 AXaIU/time, twice daily. Patients in two groups were treated for 1 week. After treatment, blood pressure, renal function, pregnancy and pregnancy complications in two groups before and after treatment were compared. Results After treatment, the systolic pressure and mean arterial pressure in the control group was significantly decreased, the systolic pressure, diastolic pressure and mean arterial pressure in the treatment group was also significantly decreased, and there were differences in the same group (P<0.05). And the diastolic pressure and mean arterial pressure in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P<0.05). After treatment, the 24 h urine protein, UA, BUN, and Scr levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And these indicators in the treatment group were significantly lower than that in the control group, with significant difference between two groups (P<0.05). After treatment, the body mass of newborns, survival cases, childbirth week, and pregnant duration prolonging in the treatment group was significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the incidence of complications in the control and treatment groups were 15.18% and 7.59%, respectively, and there were differences between two groups (P<0.05). Conclusion Low molecular weight heparin calcium combined with anisodamine has good clinical efficacy in treatment of early onset severe preeclampsia, which has a certain clinical application value.